Wolverine Trading
CLVS

Wolverine Trading’s Clovis Oncology, Inc. CLVS Stock Holding History

Wolverine Trading’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-57,100
Closed -$98K – 5639
2022
Q2 		$98K Sell
57,100
-4,200
-7% -$6.2K ﹤0.01% 3855
2022
Q1 		$101K Sell
61,300
-8,400
-12% -$16.5K ﹤0.01% 4822
2021
Q4 		$199K Buy
69,700
+100
+0.1% +$370 ﹤0.01% 4729
2021
Q3 		$315K Sell
69,600
-54,800
-44% -$264K ﹤0.01% 4634
2021
Q2 		$728K Buy
124,400
+1,100
+0.9% +$6.45K ﹤0.01% 3184
2021
Q1 		$836K Buy
123,300
+9,000
+8% +$60.3K ﹤0.01% 3000
2020
Q4 		$562K Buy
114,300
+8,300
+8% +$42K ﹤0.01% 3037
2020
Q3 		$630K Buy
106,000
+35,700
+51% +$214K ﹤0.01% 2559
2020
Q2 		$494K Buy
+70,300
New +$532K ﹤0.01% 2741
2019
Q4 		– Sell
-52,500
Closed -$210K – 5404
2019
Q3 		$210K Sell
52,500
-22,400
-30% -$181K ﹤0.01% 3525
2019
Q2 		$1.11M Buy
74,900
+28,700
+62% +$519K ﹤0.01% 1950
2019
Q1 		$1.15M Sell
46,200
-5,800
-11% -$145K ﹤0.01% 1947
2018
Q4 		$934K Sell
52,000
-13,300
-20% -$272K ﹤0.01% 2033
2018
Q3 		$1.92M Buy
65,300
+34,100
+109% +$1.32M ﹤0.01% 1713
2018
Q2 		$1.65M Hold
31,200
– – ﹤0.01% 1766
2018
Q1 		$1.65M Sell
31,200
-5,700
-15% -$333K ﹤0.01% 1766
2017
Q4 		$2.51M Sell
36,900
-5,100
-12% -$357K 0.01% 1361
2017
Q3 		$3.46M Sell
42,000
-21,000
-33% -$1.66M 0.01% 991
2017
Q2 		$5.8M Sell
63,000
-24,900
-28% -$1.52M 0.03% 596
2017
Q1 		$5.52M Buy
+87,900
New +$5.34M 0.03% 601
2016
Q4 		– Sell
-41,400
Closed -$1.43M – 5374
2016
Q3 		$1.43M Buy
41,400
+3,700
+10% +$79.4K 0.01% 1554
2016
Q2 		$568K Buy
+37,700
New +$551K ﹤0.01% 2109

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Wolverine Trading's CLVS Position: Q3 2022 in Review

Wolverine Trading sold out of Clovis Oncology, Inc. (CLVS) in Q3 2022, closing a stake of 45,133 shares — an estimated $77K sold.

Wolverine Trading first reported a position in CLVS in Q2 2016 and held it in 17 quarters. The position peaked at $6.65M in Q2 2017. 103 funds tracked by Wall St. Rank hold CLVS as of Q3 2022.

  • Wolverine Trading reported no remaining Clovis Oncology, Inc. position as of Q3 2022 after selling out during the quarter.
  • Wolverine Trading sold 45,133 Clovis Oncology, Inc. shares in Q3 2022, an estimated $77K.
  • Wolverine Trading first reported a position in Clovis Oncology, Inc. in Q2 2016 and held it in 17 quarters.
  • Wolverine Trading's Clovis Oncology, Inc. position peaked at $6.65M in Q2 2017.
  • 103 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2022.

Based on Wolverine Trading's 13F filing for Q3 2022, filed 14 Nov 2022.